文献速递认知障碍与痴呆脑血管病

阿尔茨海默病中退行性与脑血管病理的MRI测量指标

An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease.
PubMed 文献 · Neurology · 2018-09-14

该研究基于曼哈顿北部社区队列(n=1,175)开发并重复了一项结合白质高信号、梗死、海马体积和皮层厚度的MRI定量指标,并在阿尔茨海默病神经影像学倡议中用尸检、临床诊断、脑脊液生物标志物和淀粉样蛋白PET进行验证。该指标在轻度认知障碍和临床阿尔茨海默病患者中低于健康对照,与神经原纤维缠结、神经元丢失、萎缩和梗死相关,并能预测健康对照向轻度认知障碍和临床阿尔茨海默病的转化。

要点

  • 该MRI定量指标结合了脑血管和神经退行性病理,在社区队列中开发并重复。
  • 该指标在轻度认知障碍和临床阿尔茨海默病患者中低于健康对照。
  • 该指标与尸检神经原纤维缠结、神经元丢失、萎缩和梗死相关,并预测健康对照转化。

核心结论

  • 研究开发、重复并验证了一种与阿尔茨海默病临床和神经病理诊断相关、并与既定生物标志物相关的脑血管和神经退行性病理的MRI指标。

研究设计与样本

  • 横断面和纵向社区队列研究,纳入曼哈顿北部符合医疗保险资格的居民,每18-24个月随访一次,共1,175人,平均年龄78岁。
  • 从MRI量化白质高信号、梗死、海马体积和皮层厚度,组合生成与情景记忆相关的MRI指标。
  • 使用阿尔茨海默病神经影像学倡议的尸检数据、临床诊断、脑脊液生物标志物和淀粉样蛋白PET重复并验证该组合指标。

主要发现

  • 定量MRI指标在社区参与者一组(n=690)中开发,并在相似的第二组(n=485)中重复。
  • 与健康对照相比,定量MRI指标在轻度认知障碍患者中较低,在临床诊断阿尔茨海默病患者中更低。
  • 定量MRI指标在尸检亚组中与神经原纤维缠结、神经元丢失、萎缩和梗死相关,并与PET淀粉样蛋白成像及脑脊液总tau、磷酸化tau和β-淀粉样蛋白42水平相关。
  • 该MRI指标预测健康对照向轻度认知障碍和临床阿尔茨海默病的转化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop, replicate, and validate an MRI-based quantitative measure of both cerebrovascular and neurodegeneration in Alzheimer disease (AD) for clinical and potentially research purposes. METHODS: We used data from a cross-sectional and longitudinal community-based study of Medicare-eligible residents in northern Manhattan followed every 18-24 months (n = 1,175, mean age 78 years). White matter hyperintensities, infarcts, hippocampal volumes, and cortical thicknesses were quantified from MRI and combined to generate an MRI measure associated with episodic memory. The combined MRI measure was replicated and validated using autopsy data, clinical diagnoses, and CSF biomarkers and amyloid PET from the Alzheimer's Disease Neuroimaging Initiative. RESULTS: The quantitative MRI measure was developed in a group of community participants (n = 690) and replicated in a similar second group (n = 485). Compared with healthy controls, the quantitative MRI measure was lower in patients with mild cognitive impairment and lower still in those with clinically diagnosed AD. The quantitative MRI measure correlated with neurofibrillary tangles, neuronal loss, atrophy, and infarcts at postmortem in an autopsy subset and was also associated with PET amyloid imaging and CSF levels of total tau, phosphorylated tau, and β-amyloid 42. The MRI measure predicted conversion to MCI and clinical AD among healthy controls. CONCLUSION: We developed, replicated, and validated an MRI measure of cerebrovascular and neurodegenerative pathologies that are associated with clinical and neuropathologic diagnosis of AD and related to established biomarkers.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Brickman AM, Tosto G, Gutierrez J, et al. An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease. Neurology. 2018. PMID: 30217936. doi:10.1212/WNL.0000000000006310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。